The development and production of biopharmaceuticals are advancing rapidly, with novel medicines becoming increasingly complex. From amorphous small molecules and fusion proteins to antibody-drug conjugates (ADCs) and viral & synthetic delivery vectors for cell & gene therapies, understanding the structure and composition of these entities is crucial for ensuring their efficacy and manufacturability.
Join us for the first webinar in a three-part series as we explore the complementary analytical solutions that will give you deeper insights into the structural features of your biopharmaceuticals. Together, technology and biopharmaceuticals industry experts from Malvern Panalytical and Xenocs will dive into applications around nucleic acid drug products (such as mRNA vaccines and RNA therapeutics), as well as biopharmaceuticals including peptide-based therapeutics.
Présentateur
- Hanna Jankevics-Jones - Sector Marketing Director Pharma & Food, Malvern Panalytical
- Soren Skou - Managing Director Xenocs Nordic, Xenocs
Pour en savoir plus
Who should attend?
- Scientists and researchers focused on the stability of biopharmaceuticals, including peptides and LNPs
- Anyone involved in the development and production of nucleic acid drug products and biologics
What will you learn?
- Gain insights into higher-order structural changes, thermal stability, and particle size distribution
- Learn how SAXS and DSC provide critical information on drug modalities
- Understand the importance of orthogonal approaches to the structure-property relationship of biopharmaceuticals